| Autor: |
Griffith MF; Denver-Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Eastern Colorado Health Care System, Aurora, Colorado.; Department of Medicine, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado.; Department of Medicine, School of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado., Chen HP; Denver-Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Eastern Colorado Health Care System, Aurora, Colorado.; St. Louis University Center for Health Outcomes Research, St. Louis University, St. Louis, Missouri; and., Bekelman DB; Denver-Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Eastern Colorado Health Care System, Aurora, Colorado.; Department of Medicine, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado.; Department of Medicine, School of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado., Feemster LC; Denver-Seattle Center of Innovation for Veteran-Centered and Value-Driven Care and.; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Puget Sound Veterans Affairs Medical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington., Spece LJ; Denver-Seattle Center of Innovation for Veteran-Centered and Value-Driven Care and.; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Puget Sound Veterans Affairs Medical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington., Donovan LM; Denver-Seattle Center of Innovation for Veteran-Centered and Value-Driven Care and.; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Puget Sound Veterans Affairs Medical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington., Au DH; Denver-Seattle Center of Innovation for Veteran-Centered and Value-Driven Care and.; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Puget Sound Veterans Affairs Medical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington., Carey EP; Denver-Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Eastern Colorado Health Care System, Aurora, Colorado.; St. Louis University Center for Health Outcomes Research, St. Louis University, St. Louis, Missouri; and. |
| Abstrakt: |
Rationale: Patients with chronic obstructive pulmonary disease (COPD) and anxiety or depression experience more symptoms and exacerbations than patients without these comorbidities. Failure to provide beneficial COPD therapies to appropriate patients (underuse) and provision of potentially harmful therapies to patients without an appropriate indication (overuse) could contribute to respiratory symptoms and exacerbations. Anxiety and depression are known to affect the provision of health services for other comorbid conditions; therefore, underuse or overuse of therapies may explain the increased risk of severe symptoms among these patients. Objectives: To determine whether diagnosed anxiety and depression, as well as significant anxiety and depression symptoms, are associated with underuse and overuse of appropriate COPD therapies. Methods: We analyzed data from a multicenter prospective cohort study of 2,376 participants (smokers and control subjects) enrolled between 2010 and 2015. We identified two subgroups of participants, one at risk for inhaled corticosteroid (ICS) overuse and one at risk for long-acting bronchodilator (LABD) underuse based on the 2011 Global Initiative for Chronic Obstructive Lung Disease statement. Our primary outcomes were self-reported overuse and underuse. Our primary exposures of interest were self-reported anxiety and depression and significant anxiety and depression symptoms. We adopted a propensity-score method with inverse probability of treatment weighting adjusting for differences in prevalence of confounders and performed inverse probability of treatment weighting logistic regression to evaluate all associations between the exposures and outcomes. Results: Among the 1,783 study participants with COPD confirmed by spirometry, 667 (37.4%) did not have an indication for ICS use, whereas 985 (55.2%) had an indication for LABD use. Twenty-five percent ( n = 167) of patients reported ICS use, and 72% ( n = 709) denied LABD use in each subgroup, respectively. Neither self-reported anxiety and depression nor significant anxiety and depression symptoms were associated with overuse or underuse. At least 50% of patients in both subgroups with significant symptoms of anxiety or depression did not report a preexisting mental health diagnosis. Conclusions: Underuse of LABDs and overuse of ICSs are common but are not associated with comorbid anxiety or depression diagnosis or symptoms. Approximately one-third of individuals with COPD experience anxiety or depression, and most are undiagnosed. There are significant opportunities to improve disease-specific and patient-centered treatment for individuals with COPD. |
